The results of the LMS04 trial reported by Pautier et al. (Sept. 5 issue)1 are unprecedented in terms of the median progression-free and overall survival. The French Sarcoma Group should be lauded for conducting this large trial in patients with a specific sarcoma subset. However, we would like to raise a few issues.